Pfizer Inc. (NYSE:PFE) Shares Sold by Cullinan Associates Inc.

Cullinan Associates Inc. cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 63,254 shares of the biopharmaceutical company’s stock after selling 1,650 shares during the period. Cullinan Associates Inc.’s holdings in Pfizer were worth $1,678,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Quarry LP acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $31,000. Czech National Bank grew its position in shares of Pfizer by 6.9% during the 3rd quarter. Czech National Bank now owns 1,154,366 shares of the biopharmaceutical company’s stock valued at $33,407,000 after buying an additional 74,737 shares during the last quarter. GAMMA Investing LLC raised its stake in Pfizer by 48.9% during the third quarter. GAMMA Investing LLC now owns 39,904 shares of the biopharmaceutical company’s stock worth $1,155,000 after acquiring an additional 13,097 shares during the period. Diversified Trust Co boosted its stake in Pfizer by 33.8% in the third quarter. Diversified Trust Co now owns 113,505 shares of the biopharmaceutical company’s stock valued at $3,285,000 after acquiring an additional 28,658 shares during the period. Finally, Smith Anglin Financial LLC raised its position in shares of Pfizer by 2.2% during the 3rd quarter. Smith Anglin Financial LLC now owns 22,521 shares of the biopharmaceutical company’s stock worth $652,000 after purchasing an additional 495 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent research reports. Bank of America restated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a research note on Tuesday, December 10th. Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target on the stock. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Finally, Citigroup cut their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Down 1.1 %

Pfizer stock opened at $26.23 on Tuesday. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $148.62 billion, a PE ratio of 35.44, a PEG ratio of 0.66 and a beta of 0.64. The business’s 50-day simple moving average is $26.27 and its 200-day simple moving average is $27.85.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Equities research analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.56%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is currently 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.